Latest Hotspot

Promising Results for Nuvectis Pharma's NXP800 in ARID1a-Altered Ovarian Cancer

20 March 2024
3 min read

Nuvectis Pharma, Inc. has disclosed early-stage results from its continuous Phase 1b study evaluating NXP800 on individuals battling ovarian cancer that does not respond to platinum treatments and is characterized by mutations in the ARID1a gene. This condition represents a critical healthcare challenge with no adequate treatments currently available.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The NXP800 initiative aimed at tackling this medical condition has earned the status of Fast Track Designation by the United States FDA. Currently, the program is facilitating a Phase 1b clinical trial, which includes premier medical research institutions across the US and UK.

The CEO of Nuvectis, Ron Bentsur, announced, "The preliminary findings from our Phase 1b trial of NXP800 in patients with ARID1a-mutated ovarian cancer who are resistant to platinum-based therapy are encouraging. The data so far shows a response rate of 33% and a disease control rate of 100% for the cohort evaluated for efficacy, where disease control is a combination of partial responses and maintained disease stability."

Mr. Bentsur added, "In addition to these findings, we have been refining the dosing protocols, comparable to strategies used with other potent therapeutic agents, to enhance our handling of significant side effects tied to the treatment with NXP800. Our team is optimistic that these refinements will lead to greater strides in the trial and will help realize the comprehensive capabilities of NXP800 for this particular clinical context."

The NXP800 molecule is administered orally and is a unique, potentially groundbreaking activator of the GCN2 kinase. Beyond the primary study, the Mayo Clinic is partnering in another research study evaluating NXP800's effectiveness against cholangiocarcinoma, another cancer type for which the FDA has awarded the drug Orphan Drug Designation.

The commitment to advancing NXP800 for ARID1a-mutated ovarian cancer patients who do not respond to platinum treatment has secured Fast Track Designation from the FDA. In the earlier part of 2023, NXP800 made headway with a positive conclusion of its Phase 1a dose-escalation study.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 应用程序, Teams

描述已自动生成

According to the data provided by the Synapse Database, As of March 18 2024, there are 1 investigational drugs for the EIF2AK4 and HSF1 target, including 6 indications, 1 R&D institutions involved, with related clinical trials reaching 1, and as many as 8 patents.

NXP-800 is a small molecule drug that is being developed in the field of biomedicine. It targets EIF2AK4 and HSF1 and is primarily focused on treating neoplasms, specifically cholangiocarcinoma. The drug is currently in the preclinical phase, which means it is still undergoing laboratory testing and has not yet been tested on humans. NXP-800 has been designated as a Fast Track drug. This designation is given by regulatory authorities to drugs that show potential to address unmet medical needs and can expedite the development and review process. 

图形用户界面, 文本, 网站

描述已自动生成

Boehringer Ingelheim: Continuously Investing in the Development of Schizophrenia Treatment Drugs Targeting GPR52
Hot Spotlight
7 min read
Boehringer Ingelheim: Continuously Investing in the Development of Schizophrenia Treatment Drugs Targeting GPR52
19 March 2024
On March 11th, Boehringer Ingelheim partnered with Sosei Group in an exclusive deal to create and market a novel schizophrenia drug, a GPR52 agonist.
Read →
Who should not take semaglutide?
Knowledge Base
2 min read
Who should not take semaglutide?
19 March 2024
Individuals who should not take semaglutide are:Those with multiple endocrine neoplasia type 2 (MEN2),medullary thyroid cancer,diabetic ketoacidosis (DKA)
Read →
Synapse Simplified: How to Find Ketoconazole Information
Drug Insights
2 min read
Synapse Simplified: How to Find Ketoconazole Information
19 March 2024
Ketoconazole, a diminutive molecular compound, functions as an inhibitor of CYP51A1.
Read →
Preliminary MTX-101 Data for Autoimmune Management Unveiled by Mozart Therapeutics at 2024 SOT Meeting
Latest Hotspot
3 min read
Preliminary MTX-101 Data for Autoimmune Management Unveiled by Mozart Therapeutics at 2024 SOT Meeting
19 March 2024
Mozart Therapeutics Showcases Preliminary Data for Key Project, MTX-101, Aimed at Autoimmune Condition Management, at the 2024 Society of Toxicology Gathering.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.